SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Supernus, Inc. (borrower) entered into a credit agreement dated November 2, 2026 with Citibank, N.A. as administrative agent and multiple lenders. The facility consists of a $650M closing date term loan commitment. The agreement contains standard commercial lending terms including financial covenants (leverage ratios, interest coverage), representations, affirmative and negative covenants, and secured obligations backed by collateral. The loan is tied to the Specified Merger (acquisition of Supernus by Indivior Pharmaceuticals/Artemis Merger Sub) and refinancing of existing debt.
Why this rating
Standard acquisition financing. $650M loan is ~38% of $1.7B market cap, material but ordinary for M&A. Routine credit agreement with boilerplate terms; no unexpected conditions or material changes to business disclosed.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.